 Prospective, single center, clinical study of SRT2104 administered orally. Randomized, placebo-controlled, single-blind, multiple-dose, dose-escalation inpatientoutpatient study to assess the safety and pharmacokinetics PK of SRT2104 in healthy male volunteers. Forty-two 42 subjects aged 18-55, who fulfill the inclusionexclusion criteria, will be enrolled in this study. Seven cohorts of six subjects each will be examined. Subjects within each cohort will be randomized 4:2 to receive SRT2104 at one of seven escalating doses A, B, C, D, E, F, or G, likely to be 0.03, 0.1, 0.25, 0.5, 1.0, 2.0, or 3.0 gday or placebo. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving active treatment and one subject receiving placebo. The remainder of subjects within each cohort will be dosed on Day 2 of the single dose period with three subjects receiving active treatment and one subject receiving placebo assuming that no safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. 